Systems and methods for performing online extracorporeal photopheresis

ABSTRACT

Systems and methods for performing online extracorporeal photopheresis of mononuclear cells are disclosed. Whole blood is removed from a patient and introduced through a processing set into a separation chamber to separate the desired cell population from the blood. The separated cell population is processed through the set which is associated with a treatment chamber where the cells are treated. Once treated, the cells are returned to the patient. The processing set remains connected to the patient during the entire ECP treatment procedure and provides an online, sterile closed pathway between the separation chamber and the treatment chamber.

FIELD OF THE DISCLOSURE

The present disclosure relates to systems and methods for performingonline extracorporeal photopheresis (“ECP”). More particularly, thepresent disclosure is directed to systems and methods for removingmononuclear cells from a patient, treating the removed cells andreturning treated cells to the patient in a single “on-line” procedureutilizing a multifunctional apheresis device, an independent andseparately housed device for irradiating cells with light and adisposable processing set that provides a sterile closed pathway betweenthe apheresis device and the irradiation device.

BACKGROUND

Whole blood is made up of various cellular and non-cellular componentssuch as red cells, white cells and platelets suspended in its liquidcomponent, plasma. Whole blood can be separated into its constituentcomponents (cellular, liquid or other), and the separated component canbe administered to a patient in need of that particular component.

The administration of blood and/or blood components is common in thetreatment of patients suffering from disease. Rather than infuse wholeblood, it is more typical that individual components be administered tothe patient(s) as their needs require. For example, administration(infusion) of platelets is often prescribed for cancer patients whoseability to make platelets has been compromised by chemotherapy. Infusionof white blood cells (i.e., mononuclear cells), after the cells haveundergone some additional processing or treatment, may also beprescribed for therapeutic reasons including treatment of diseases thatspecifically involve the white blood cells. Thus, it is often desirableto separate and collect the desired blood component from whole blood andthen treat the patient with the specific blood component. The remainingcomponents may be returned to the donor or retained for other uses.

There are several diseases or disorders which are believed to primarilyinvolve mononuclear cells, such as cutaneous T-cell lymphoma, organallograft rejection after transplantation and autoimmune diseases suchas rheumatoid arthritis, systemic sclerosis, among others.

Cutaneous T-cell lymphoma (CTCL) is a term that is used to describe awide variety of disorders. Generally, CTCL is a type of cancer of theimmune system where T-cells (a type of mononuclear cell) mutate or growin an uncontrolled way, migrate to the skin and form itchy, scalyplaques or patches. More advanced stages of the disease also affect thelymph nodes. Therapeutic treatment options for CTCL have previously beenlimited. While chemotherapy has been utilized, this particular form oftreatment also has many associated undesirable side effects, such aslowered resistance to infection, bleeding, bruising, nausea, infertilityand hair loss, just to name a few.

Organ allograft rejection may be characterized as the rejection oftissues that are foreign to a host, including transplanted cardiactissue as well as lung, liver and renal transplants. Immunosuppressiondrug therapy following transplantation is common. However, there arepotential drawbacks including reoccurring infection due to thecompromised competence of the immune system caused by this type oftherapy.

Similarly, graft versus host disease (GVHD) is a complication that canoccur after a stem cell or bone marrow transplant in which the newlytransplanted material attacks the transplant recipient's body. Thedifferences between the donor's cells and recipient's tissues oftencause T-cells from the donor to recognize the recipient's body tissuesas foreign, thereby causing the newly transplanted cells to attack therecipient. GVHD may complicate stem cell or bone marrow transplantation,thereby potentially limiting these life-saving therapies. Therefore,after a transplant, the recipient is usually administered a drug thatsuppresses the immune system, which helps reduce the chances or severityof GVHD. See Dugdale, David C., et al. “Graft-Versus-Host Disease,”MedlinePlus A.D.A.M Medical Encyclopedia, Updated Jun. 2, 2010.

Autoimmune diseases, including rheumatoid arthritis (RA) and progressivesystemic sclerosis (PSS), can be characterized by an overactive immunesystem which mistakes the body's own tissues as being a foreignsubstance. As a result, the body makes autoantibodies that attack normalcells and tissues. At the same time, regulatory T-cells, which normallyfunction to regulate the immune system and suppress excessive reactionsor autoimmunity, fail in this capacity. This may lead to among otherthings, joint destruction in RA and inflammation of the connectivetissue in PSS.

Where existing therapies for treating one or more diseases may result incertain unintended side effects, additional treatment may be desired orrequired. One known procedure which has been shown to be effective inthe treatment of diseases and/or the side effects of existing therapiesinvolving mononuclear cells is extracorporeal photopheresis or “ECP”.Extracorporeal photopheresis (also sometimes referred to asextracorporeal photochemotherapy) is a process that includes: (1)collection of mononuclear cells (MNC) from a patient, (2)photoactivation treatment of the collected MNC cells; and (3) reinfusionof the treated cells (MNC) back to the patient. More specifically, ECPinvolves the extracorporeal exposure of peripheral blood mononuclearcells combined with a photoactive compound, such as 8-methoxypsoralen or“8-MOP” which is then photoactivated by ultraviolet light, followed bythe reinfusion of the treated mononuclear cells. It is believed that thecombination of 8-MOP and UV radiation causes apoptosis or programmedcell death of ECP-treated T-cells.

Although the precise mechanism of action in ECP treatment (in thedifferent disease states) is not fully known, according to earlytheories, it was believed that photoactivation causes 8-MOP toirreversibly covalently bind to the DNA strands contained in the T-cellnucleus. When the photochemically damaged T-cells are reinfused,cytotoxic effects are induced. For example, a cytotoxic T-cell or “CD8+cell” releases cytotoxins when exposed to infected or damaged cells orotherwise attacks cells carrying certain foreign or abnormal moleculeson their surfaces. The cytotoxins target the damaged cell's membrane andenter the target cell, which eventually leads to apoptosis or programmedcell death of the targeted cell. In other words, after the treatedmononuclear cells are returned to the body, the immune system recognizesthe dying abnormal cells and begins to produce healthy lymphocytes(T-cells) to fight against those cells.

In addition to the above, it has also been theorized that extracorporealphotopheresis also induces monocytes (a type of mononuclear cell) todifferentiate into dendritic cells capable of phagocytosing andprocessing the apoptotic T-cell antigens. When these activated dendriticcells are re-infused into systemic circulation, they may cause asystemic cytotoxic CD8+ T-lymphocyte-mediated immune response to theprocessed apoptotic T-cell antigens like that described above. It willbe appreciated that other possible mechanisms of action may be involvedin achieving the benefits that have been observed from the ECP treatmentof mononuclear cells and the subsequent benefits to patients undergoingECP based therapies.

More recently, it has been postulated that ECP may result in an immunetolerant response in the patient. For example, in the case of graftversus-host disease, the infusion of apoptotic cells may stimulateregulatory T-cell generation, inhibit inflammatory cytokine production,cause the deletion of effective T-cells and result in other responses.See Peritt, “Potential Mechanisms of Photopheresis in Hematopoietic StemCell Transplantation,” Biology of Blood and Marrow Transplantation12:7-12 (2006). While presently the theory of an immune tolerantresponse appears to be among the leading explanations, there exist othertheories as to the mechanism of action of ECP relative tograft-versus-host disease, as well as other disease states.

Systems for performing ECP include, for example, the UVAR XTSPhotopheresis System available from Therakos, Inc., of Exton, Pa.Further details of performing ECP on the Therakos system can be found,for example, in U.S. Pat. No. 5,984,887.

While the clinical benefits of ECP have been recognized, the use of ECPis not without its own drawbacks, including the systems and methods bywhich the ECP treatment is performed. For example, there are currentlytwo commonly used methods for performing photopheresis—online andoffline methods. In online methods, a dedicated photopheresis device,such as the Therakos device mentioned above, is used to perform theentire therapy including reinfusion of treated MNCs. Such devices are“dedicated” photopheresis devices, designed only for performingphotopheresis and cannot perform other collection protocols needed in ahospital or blood processing setting including, for example,multifunctional apheresis protocols for collection of platelets, plasma,RBCs, granulocytes and/or perform plasma/RBC exchange protocols. Inoffline photopheresis methods, a multifunctional apheresis device may beused to collect mononuclear cells. The collected MNCs, typicallycontained in one or more collection containers, are severed or otherwiseseparated from the tubing set used during collection, where they arelater treated in a separate irradiation or UVA light device followed bymanual reinfusion of the treated cells to a patient. However, duringsuch offline methods, when the cells are transferred from the apheresisdevice to the irradiation device (which device may be located in anotherroom or laboratory) communication with the donor must be severed andaccordingly, the cells detached from the donor. Thus, additionaltraceability procedures are required to insure that the treated MNCproduct is ultimately reinfused into the correct donor.

Therefore, it would also be desirable to develop “on line” systems andmethods for providing ECP-treated mononuclear cells which avoids anyadditional product labeling and/or traceable handling requirementsbecause the MNC product never leaves the disposable set which remainsconnected to the donor during the entire ECP treatment procedure. Tothis end, the systems and methods described herein include (1) amultifunctional automated apheresis device for harvesting MNCs fromwhole blood and reinfusing treated MNCs to a patient, (2) an irradiationdevice housed separately from the apheresis device which irradiates MNCscombined with 8-MOP to obtain treated MNC and (3) a disposable set whichproves a sterile, closed pathway between the apheresis device andirradiation device and which remains connected to the patient during anentire photopheresis procedure. Use of a multifunctional apheresisdevice in accordance with the systems and methods described hereinallows a hospital or medical facility to procure and maintain fewerapheresis devices, taking up less space and being more economical thanhaving to acquire dedicated photopheresis devices used solely forperforming ECP treatment, while also retaining a sterile closed pathwaybetween two separate processing devices.

SUMMARY

In one aspect, the present disclosure is directed to an onlineextracorporeal photopheresis system. The system comprises a disposablefluid circuit comprising a processing chamber for separating whole bloodinto one or more components including mononuclear cells and at least onestorage container adapted to receive mononuclear cells. At least aportion of the container is transparent to light of a selectedwavelength. The system further comprises a separation device adapted toreceive the processing chamber for effecting separation of mononuclearcells from whole blood and an irradiation device housed separately fromthe separation device adapted to receive the mononuclear cell storagecontainer for treating the cells with a selected dose of light. Thedisposable fluid circuit provides a sterile closed pathway between theseparation device and the irradiation device.

In another aspect, the present disclosure is directed to methods forperforming an online extracorporeal photopheresis treatment procedure.The method comprises the steps of providing a disposable fluid circuitcomprising a processing chamber for separating whole blood into one ormore components including mononuclear cells and at least one treatmentcontainer adapted to receive mononuclear cells and separating from asource of whole blood a mononuclear cell product on an apheresis deviceadapted to receive the processing chamber for effecting separation ofmononuclear cells from whole blood. The method further comprisescombining the cell product with an activation agent and exposing thecell product to light in an irradiation device that is housed separatelyfrom the apheresis device to obtain a treated cell product. The treatedcell product is then returned to the source and at least a portion ofthe fluid circuit remains connected to the source for the duration ofthe treatment procedure. The fluid circuit provides a sterile closedpathway between the separation chamber and the treatment chamber.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram generally showing the mechanical components of aphotopheresis treatment as described herein;

FIG. 2 is a partial perspective view of a multifunctional apheresisseparator useful in the methods and systems described herein;

FIG. 3 is a perspective view of a processing container (separationchamber) of the processing set used with the separator of FIG. 2;

FIG. 4 is a diagram of the fluid circuit useful in the collection,treatment and reinfusion of mononuclear cells as described herein; and

FIG. 5 is a flow chart setting forth the steps of the method of aphotopheresis treatment as described herein.

DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS

The subject matter of the present disclosure relates generally tosystems and methods for performing online extracorporeal photopheresis(ECP) treatment of mononuclear cells utilizing a multifunctionalautomated apheresis device, a disposable fluid circuit and anindependent irradiation device housed separately from the apheresisdevice.

FIG. 1 shows, in general, the mechanical components that make up thesystem and that are used in the methods described herein. In accordancewith the present disclosure, the system includes a separation component10 and a treatment (i.e., irradiation) component 20. Preferably,irradiation component 20 is independent and housed separately fromseparation component 10. Although separately housed and independentdevices, it is preferable that separation device 10 and irradiationdevice 20 are located adjacent to each other. In one example, separationdevice 10 and irradiation 20 may be located in the same room butphysically spaced several feet or yards from each other. Irradiationdevice 20 may be on a table top located near or adjacent to separationcomponent 10 allowing an operator or clinician to have access to bothdevices during a particular treatment procedure. In accordance with thesystems and methods described herein a patient is connected to a bloodprocessing set, i.e., fluid circuit 200. As generally illustrated inFIGS. 1 and 4, fluid circuit 200 provides a sterile closed pathwaybetween separation component 10 and irradiation component 20. The systemdescribed herein also optionally includes a washing component which,preferably, is housed within the separation component. Preferably, theseparation component 10 and washing component are one and the same, aswill be described in greater detail below.

With reference to FIG. 1, whole blood is withdrawn from the patient andintroduced into the separation component 10 where the whole blood isseparated to provide a target cell population. In a preferred embodimentin accordance with the present disclosure, the target cell populationmay be mononuclear cells. Other components separated from the wholeblood, such as red blood cells and platelets may be returned to thepatient or collected in pre-attached containers of the blood processingset.

The separated target cell population, e.g., mononuclear cells, is thentreated and irradiated in treatment component 20. As discussed above, inaccordance with the present disclosure, treatment of mononuclear cellsinvolves the photoactivation of a photoactive agent that has beencombined with the mononuclear cells. Once treated, the mononuclear cellsmay optionally be provided to a washing component, which, as shown inFIG. 1, is housed within separation component 10 and, preferably, is oneand the same. The treated mononuclear cells are separated from thesupernatant and the concentrated cells may be returned to the patient.The supernatant liquid will typically include excess and unboundphotoactivation agent. Optionally, the concentrated cells may further becombined with a suitable wash solution within separation/washingcomponent 10. If washing of the treated mononuclear cells is performed,the suspension of mononuclear cells in a wash solution is then subjectedto a centrifugal field (or other environment which can effect separationof the fluid components), whereby the mononuclear cells are concentratedand separated from the supernatant. The supernatant liquid may includeany remaining unbound photoactivation agent. Supernatant may then bediverted to an appropriate waste container, while the treatedmononuclear cells are returned to the patient, as generally shown inFIG. 1.

Apparatus useful in the collection (and washing) of mononuclear cellsinclude the Amicus® Separator made and sold by Fenwal, Inc., of LakeZurich, Ill. Mononuclear cell collections using a device such as theAmicus® are described in greater detail in U.S. Pat. No. 6,027,657, thecontents of which is incorporated by reference herein in its entirety.Preferably, the apparatus used for the harvesting, collection andreinfusion of mononuclear cells in accordance with the apparatus andmethods described herein is a “multifunctional” automated apheresisdevice, as is the case with the Amicus® Separator. In other words, it ispreferable that the separation component 10 be an multifunctionalautomated apparatus that can perform various collection protocols and/orserve multiple purposes, as may be needed by a particular hospital orfacility, such that it can be used not only in the systems and methodsfor performing photopheresis treatment of MNC as described herein, butcan also be used for other purposes including the collection of bloodand blood components including platelets, plasma, red blood cells,granulocytes and/or perform plasma/RBC exchange, among other functionsrequired by the hospital or medical facility. One benefit of the systemsand described herein, in which a fluid processing circuit engages both amultifunctional apheresis device and an irradiation device, is that a“dedicated” photopheresis device that is designed only to perform ECPtreatment, but which does not perform any other functions, is notrequired.

Briefly, FIGS. 2-4 show a representative blood centrifuge 10 with fluidcircuit 200 mounted thereon (FIG. 2), the fluid circuit (FIG. 4) havinga blood processing container 14 (see FIG. 3) defining a separationchamber suitable for harvesting mononuclear cells (MNC) from wholeblood. As shown in FIG. 2, a disposable processing set or fluid circuit200 (which includes container 14) is mounted on the front panel ofcentrifuge 10. The processing set (fluid circuit 200) includes aplurality of processing cassettes 23L, 23M and 23R with tubing loops forassociation with peristaltic pumps on device 10. Fluid circuit 200 alsoincludes a network of tubing and pre-connected containers forestablishing flow communication with the patient and for processing andcollecting fluids and blood and blood components, as shown in greaterdetail in FIG. 4. As seen in FIGS. 2 and 4, disposable processing set200 may include a container 60 for supplying anticoagulant, a wastecontainer 62 for collecting waste from one or more steps in the processfor treating and washing mononuclear cells, a container 64 for holdingsaline or other wash or resuspension medium, a container 66 forcollecting plasma, a container 68 for collecting the mononuclear cellsand, optionally, container 69 for holding the photoactivation agent.

In accordance with the methods and systems described herein, container68 may also serve as the illumination container, and preferably,illumination container 68 is pre-attached to and integral with thedisposable set 200. Alternatively, container 68 may be attached to set200 by known sterile connection techniques, such as sterile docking orthe like. In FIG. 2, container 68 is shown as suspended from device 10.However, container 68 may be housed within an adjacent separately housedirradiation device 20 (as shown by broken lines in FIG. 4), therebyeliminating the step of having the operator place container 68 intoirradiation device 20. It will be appreciated that the tubing leading toand/or from container 68 in fluid circuit 200 is of a sufficient lengthto reach an irradiation device 20 that is adjacent to but housedseparately from the separation device. In other words, regardless ofwhether container 68 is placed within irradiation device 20 prior totreatment or whether it is manually placed in device 20 during or aftercells have been collected therein, the one or more lengths of tubingcommunicating with bag 68 as well as other tubing portions of fluidcircuit 200 are preferably long enough to provide a sterile closedpathway between the two independent and separately housed separationdevice 10 and irradiation device 20 such that container 68 does not haveto be separated or otherwise disconnected from the fluid circuit forcells collected therein to be treated in irradiation container 20.

With reference to FIG. 4, fluid circuit includes inlet line 72, ananticoagulant (AC) line 74 for delivering AC from container 60, an RBCline 76 for conveying red blood cells from chamber 12 of container 14 tocontainer 67, a platelet-poor plasma (PPP) line 78 for conveying PPP tocontainer 66 and line 80 for conveying mononuclear cells to and fromseparation chamber 14 and collection/illumination container 68. As willbe known to those of skill in the art, the blood processing set includesone or more venipuncture needle(s) for accessing the circulatory systemof the patient. As shown in FIG. 4, fluid circuit 200 includes inletneedle 70 and return needle 82. In an alternative embodiment, a singleneedle can serve as both the inlet and outlet needle.

Fluid flow through fluid circuit 200 is preferably driven, controlledand adjusted by a microprocessor-based controller in cooperation withthe valves, pumps, weight scales and sensors of device 10 and fluidcircuit 200, the details of which are described in the previouslymentioned U.S. Pat. No. 6,027,657.

In accordance with the present disclosure, the fluid circuit is furtheradapted for association with the treatment component (i.e., irradiationdevice) 20. Apparatus for the irradiation of the mononuclear cells arealso known and are available from sources such as Cerus Corporation, ofConcord, Calif. One example of a suitable irradiation device isdescribed in U.S. Pat. No. 7,433,030, the contents of which is likewiseincorporated by reference herein in its entirety. As shown and describedin U.S. Pat. No. 7,433,030, irradiation device preferably includes atray or other holder for receiving one or more containers duringtreatment. Other irradiation devices may also be suitable for use withthe method and system described herein, including devices available fromMacopharma and/or Vilber Lourmet.

As noted above, separation chamber 12 is defined by the walls of aflexible processing container 14 carried within an annular gap definedby a rotating spool element 18 and an outer bowl element (not shown).The processing container 14 takes the form of an elongated tube which iswrapped about the spool element 18 before use. The bowl and spoolelement 18 are pivoted on a yoke between an upright position and asuspended position, also not shown.

When upright, the bowl and spool element 18 are presented for access bythe user. A mechanism permits the spool 18 and bowl elements to beopened so that the operator can wrap the container 14 about the spoolelement 18, as FIG. 3 shows. Pins 150 on the spool element 18 engagecutouts on the container 14 to secure the container 14 on the spoolelement 18. In operation, the centrifuge 10 rotates the suspended bowland spool element 18 about an axis 28, creating a centrifugal fieldwithin the processing chamber of container 14.

The radial boundaries of the centrifugal field are formed by theinterior wall of the bowl element and the exterior wall 26 of the spoolelement 20. The interior bowl wall defines the high-G wall. The exteriorspool wall 26 defines the low-G wall. Further details of the mechanismfor causing relative movement of the spool 18 and bowl elements as justdescribed are disclosed in U.S. Pat. No. 5,360,542 entitled “CentrifugeWith Separable Bowl and Spool Elements Providing Access to theSeparation Chamber,” which is also incorporated herein by reference.

Turning now to the method of treating mononuclear cells, as shown inFIG. 5, whole blood is withdrawn from a patient (step 30) through inletneedle 70 and introduced into the separation chamber 12 of container 14of processing set 200, where the whole blood is subjected to acentrifugal field. The centrifugal field will separate the target cellpopulation, i.e., mononuclear cells, from red blood cells, platelets andplasma (step 32). As discussed above, the components such as red bloodcells and platelets may be returned to the patient or may be diverted toa container (e.g., container 67) for further processing.

Collection of the mononuclear cells may proceed in one or more cycles.The number of processing cycles conducted in a given therapeuticprocedure will depend upon the total volume of MNC to be collected. Forexample, in a representative procedure, five collection cycles may beperformed sequentially. During each cycle about 1500-3000 ml of wholeblood can be processed to obtain a MNC volume of about 3 ml per cycleand a total volume of 15 ml of MNC. As shown in step 32 of FIG. 5, thefinal volume of mononuclear cells is then provided for further treatmentin accordance with the present disclosure. Of course, the collection ofMNC is not limited to the method described above. MNCs may be collectedin any manner known to those of skill in the art, but preferably using amultifunctional apheresis device.

Effective treatment of the mononuclear cells with light may require thatthe amount of collected mononuclear cells have a suitable hematocrit.Thus, it may be desired or even necessary to dilute the mononuclearcells with a diluting solution such as plasma or saline, as shown instep 33. In the example described above, approximately 15 ml of MNC maybe diluted in about 200 ml of plasma.

The diluted mononuclear cells (in container 68) are then combined withthe suitable photoactivation agent in step 34. Alternatively, thedesired volume of the agent may be pre-added to the container. Asdiscussed above, for ECP treatment, the compound 8-methoxypsoralen(8-MOP) has been shown to be an effective photoactivation agent.However, other suitable photoactivation agents may be used, including,for example, a psoralen compound. In one example, the system, under thedirection of the microprocessor-based controller, may be programmed toautomatically deliver the desired amount of photoactive agent from, forexample, container 69 before or after the MNC collection, based on thevolume of MNC collected or to be collected. For example, 8-MOP may bepre-added to container 68 at the beginning of a particular procedure oralternatively, added to the MNCs collected in the container just priorto irradiation. The 8-MOP is combined with the collected and dilutedmononuclear cells to arrive at a mixture having a final 8-MOPconcentration of 200 nanograms/mL and/or any effective amount.Typically, the mononuclear cells may be combined with thephotoactivation agent to arrive at a final 8-MOP concentration in arange of about 100 to 300 nanograms/mL. The 8-MOP or otherphotoactivation agent may be added directly to container 68 by a syringethrough a port in the container, or added elsewhere in fluid circuit 200also by a syringe.

As noted above, the mononuclear cells collected in accordance with themononuclear cell collection process described above may be collected incontainer 68 that is suitable for irradiation by light of a selectedwavelength. By “suitable” it is meant that the walls of the containerare sufficiently transparent to light of the selected wavelength toactivate the photoactive agent. In treatments using UVA light, forexample, container walls made of ethylene vinyl acetate (EVA) aresuitable. Accordingly, container 68 in which the mononuclear cells arecollected may serve both as the collection container and the irradiationcontainer. Container 68 may placed inside irradiation device 20 by theoperator or more preferably, may be placed inside the irradiationchamber of irradiation device 20 at the beginning of the ECP procedureand prior to whole blood withdrawal (as shown by the broken linesrepresenting device 20 in FIG. 4). In any event, container 68 preferablyremains integrally connected to the remainder of fluid circuit 200during the entire procedure, thereby maintaining the closed orfunctionally closed condition of fluid circuit 200.

As noted above, the fluid circuit 200 is adapted for association withthe separation device 10 and with the treatment component (i.e.,irradiation device) 20. It will be appreciated that the irradiationdevice does not have to be integral or even associated with theseparation device 10. In fact, the irradiation device 20 is preferablyan “adjunct” or independently housed irradiation device 20 used toperform the photopheresis therapy and located adjacent to or in aspaced-apart location from device 10. However, the disposable set 200(including irradiation container 68) remains connected to the patientduring the entire ECP treatment procedure and provides a sterile closedpathway between separation device 10 and the irradiation device 20.

Automated control of the MNC collection and the irradiation treatmentmay be effected by the microprocessor-based controller of the respectiveseparation device 10 and irradiation device 20 with some operator inputfor each device. Alternatively, operation of both separation device 10and irradiation device 20 and the process steps carried out by each maybe remotely controlled by a separate controller (e.g., a computer) thatcommunicates with both.

The mononuclear cells with photoactivation agent (8-MOP) are thenirradiated for a selected period of time (step 36). In one non-limitingexample, during treatment, the mononuclear cell product may be exposedto UV bulbs having a wavelength in the UVA range of about 320 nm to 400nm for a selected period of time, such as approximately 10-60 minutes,resulting in an average UVA exposure of approximately 0.5-5.0 J/cm² anduse preferably approximately 1-2 J/cm² or even more preferablyapproximately 1.5 J/cm² per lymphocyte.

Once treatment is complete, the treated mononuclear cells may bereturned to separator 10 (and more specifically, the separation chamber12 of container 14) as shown in step 38 of FIG. 5. For example, one ofthe pumps associated with cassette 23R may be actuated (automatically bythe controller or under the manual control of the operator) to withdrawthe treated MNC from container 68 and introduce the MNC into chamber 12of container 14. Once inside chamber 12, the MNC may be concentrated(step 40). Supernatant, which will include unbound photoactivation agentis separated from the concentrated and treated cells and diverted to awaste container.

Concentrating treated MNCs prior to reinfusion allows for theconcentrated cells to have a smaller total volume as compared toun-concentrated cells, and as a result, a smaller volume of concentratedMNCs may be reinfused to a patient faster. The concentrated cells may beresuspended in a suitable resuspension medium (e.g., plasma, saline) asshown in step 43 and returned to the patient. Optionally, prior toreturn to the patient, the concentrated and treated cells may becombined with a suitable wash solution (step 42), supplied (by thepumping action of pumps associated with cassette 23R) from containers 66and/or 64 (see FIG. 4) is added to the concentrated cells.

Where the concentrated cells are optionally combined with wash solution(as per step 42), the mononuclear cells with wash solution within thechamber 12 (of container 14 of the disposable processing set 200) aresubjected to a centrifugal field. The MNC are separated from remainingsupernatant (step 44) under the field of centrifugal force. Anyremaining unbound and excess photoactive agent will be separated fromthe concentrated mononuclear cells and suspended in the supernatant. Thesupernatant may then be withdrawn to a waste container 62 (FIG. 4) whilethe concentrated and washed mononuclear cells may be resuspended with aresuspension solution (such as, but not limited to, plasma or saline) asshown in step 45, and returned back to the patient, as shown in step 46of FIG. 5. It will be appreciated that the step of washing themononuclear cells may be repeated, as necessary. Solutions suitable forwashing mononuclear cells include saline, plasma, or any other solutionthat is compatible with the mononuclear cell apheresis.

It will also be appreciated that the steps described above arepreferably performed with the patient continuously connected to thesystem. In that regard, the entire treatment, including the washing ofthe MNC, is deemed to be an “on-line” procedure. Thus, in accordancewith the systems and methods described herein, a multifunctionalapheresis device 10, a disposable set 200 and an independent irradiationdevice 20 may be used to perform an online ECP treatment procedure. Morespecifically, a multifunctional apheresis device 10 is preferably usedto collect MNCs from a patient and transfer the MNCs to an irradiationcontainer 68 which is pre-attached or sterile connected to disposableset 200. MNCs combined with 8-MOP in container 68 are irradiated indevice 20 resulting in treated MNCs. The treated MNC are conveyedthrough the disposable set 200 back into device 10 for reinfusion to thepatient, all while at least a portion of the disposable set 200 remainsconnected to the donor, thus maintaining a closed “online” ECPtreatment.

As previously mentioned, the online nature of the systems and methodsdescribed herein avoid the necessity for additional MNC product labelingor handling, as the mononuclear cells never leave the disposable set(and irradiation container 68 is never disconnected from the set) duringthe entire ECP treatment procedure. In other words, the disposable set200 provides a sterile, closed pathway between the multifunctionalapheresis device 10 and the irradiation device 20 such that from thetime MNCs are harvested from the patient, to the time that the ECPtreated MNCs are reinfused to the patient, an online closed system ismaintained and reinfusion to the correct patient is ensured.

In a further embodiment, it may be desirable to cryopreserve at least aportion of fresh ECP treated and washed cells that remain after aselected volume (i.e., a single therapeutic dose) of treated cells areadministered to a patient.

It will be understood that the embodiments described above areillustrative of some of the applications of the principles of thepresent subject matter. Numerous modifications may be made by thoseskilled in the art without departing from the spirit and scope of theclaimed subject matter, including those combinations of features thatare individually disclosed or claimed herein. For these reasons, thescope hereof is not limited to the above description.

The invention claimed is:
 1. An online extracorporeal photopheresissystem comprising: (a) a disposable fluid circuit comprising: i. aprocessing chamber for separating whole blood into one or morecomponents including mononuclear cells, ii. at least one storagecontainer adapted to receive mononuclear cells wherein at least aportion of said container is transparent to light of a selectedwavelength, (b) a freestanding separation device having said processingchamber received therein for effecting separation of said mononuclearcells from whole blood, (c) a freestanding irradiation deviceindependent of, and spaced apart and housed separately from, saidseparation device and having said mononuclear cell storage containerreceived therein simultaneously with the processing chamber beingreceived in the separation device for treating said mononuclear cellswith a selected dose of light, (d) a controller separate from theseparation device and the irradiation device for communicating with andcontrolling both devices, the controller configured to i. dilute themononuclear cells received in the storage container with a dilutingsolution comprising saline or plasma prior to activation of theirradiation device, ii. concentrate the irradiated diluted mononuclearcells by separating supernatant liquid, iii. combine the concentratedmononuclear cells with a wash solution, and iv. separate the combinationinto a concentrated washed cell product and supernatant liquid, (e)wherein said disposable fluid circuit provides a sterile closed pathwaybetween said processing chamber when mounted in said separation deviceand said storage container when mounted in said irradiation device. 2.The system of claim 1 further comprising a washing component forconcentrating a treated desired cell population and separating saidtreated cell population into a concentrate of said treated cellpopulation and a supernatant fluid.
 3. The system of claim 2 whereinsaid separation component and said washing component comprise acentrifugation device.
 4. The system of claim 3 wherein said separationcomponent and said washing component comprise the same centrifugationdevice.
 5. The system of claim 1 wherein the controller is configured toautomatically deliver a desired amount of photoactive agent to thestorage container.
 6. The system of claim 5 wherein the storagecontainer comprises a port through which the photoactive agent isdelivered to the storage container.
 7. A method for performing anextracorporeal photopheresis procedure comprising the steps of: a)obtaining a disposable fluid circuit comprising a separation chamber forseparating a biological fluid into one or more components including acell product, and at least one treatment container adapted to receivesaid cell product, said circuit providing a sterile closed pathwaybetween the separation chamber and the treatment container, b) mountingsaid separation chamber onto a freestanding apheresis device andmounting said treatment container onto an freestanding irradiationdevice that is independent of, and spaced apart and separate from, saidapheresis device so that said separation chamber and treatment containerare simultaneously mounted in their respective devices with thedisposable fluid circuit forming a closed fluid pathway between theapheresis device and the irradiation device, said apheresis deviceincluding at least one pump for effecting fluid flow through saidcircuit, c) utilizing a controller separate from each of the apheresisdevice and the irradiation device for controlling both devices, d)introducing from a source of biological fluid a volume of saidbiological fluid into said separation chamber and separating said cellproduct from said volume of biological fluid inside said separationchamber, e) combining said separated cell product with a selected amountof an activation agent, f) introducing said combined separated cellproduct and activation agent into said treatment container by action ofsaid at least one pump of said apheresis device; g) diluting theseparated cell product with a diluting solution comprising saline orplasma; h) treating said combined separated cell product combined andactivation agent with light in said irradiation device; i) withdrawingsaid treated cell product from said treatment container by the action ofsaid at least one pump of said apheresis device; j) concentratin aidtreated cell product and separating supernatant liquid from saidconcentrated cells; k) combining said concentrated treated cell productwith a wash solution; and l. separating said combination into aconcentrated washed cell product and supernatant.
 8. The method of claim7 further comprising returning said exposed cell product to said source,wherein at least a portion of said fluid circuit remains connected tosaid source for the duration of said treatment procedure.
 9. The methodof claim 7 comprising concentrating said treated cell product bysubjecting the treated cell product to a centrifugal field.
 10. Themethod of claim 9 further comprising resuspending said treated andconcentrated cell product in a solution.
 11. The method of Claim 7wherein said wash solution is plasma.
 12. The method of Claim 7 whereinsaid wash solution is saline.
 13. The method of claim 7 wherein saidcell product comprises mononuclear cells.
 14. The method of claim 7 saidactivation agent comprises 8-methoxypsoralen and the controller isconfigured to automatically deliver a desired amount of photoactiveagent to the treatment container.
 15. The method of Claim 7 wherein saidsupernatant includes unbound activation agent.
 16. The method of claim 7wherein said light is in the ultraviolet range.
 17. The method of claim16 wherein said light is in the UV-A range.
 18. The method of claim 7wherein the separated cell product comprises mononuclear cells having atotal volume of approximately 15 ml and the diluting solution comprisesapproximately 200 ml of plasma.